Skip Navigation LinksHome > December 2011 - Volume 17 - Issue > Health related quality of life results through week 22 from...
Inflammatory Bowel Diseases:
Clinical Poster Presentations

Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's disease: P‐39.

Sands, BE1; Gasink, C2; Gao, L‐L2; Blank, MA2; Johanns, J2; Guzzo, C2; Chiou, C‐F2; Sandborn, WJ3; Hanauer, SB4; Targan, S5; Rutgeerts, P6; Ghosh, S7; de Villiers, W8; Panaccione, R9; Greenberg, G10; Schreiber, S11; Lichtiger, S1; Feagan, BG12

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login